Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...
Opens in a new tab or window GLP-1 receptor agonist or SGLT2 inhibitor prescribing became ... in characteristics for patients prescribed these drug suggest their use "was intended to address ...
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Merck and Pfizer are to take on the crowded SGLT2 ... day at list price. The US approval has achieved, the companies await similar clearance in Europe, the other leading market for the drugs.
"If we want to maximize the benefits of SGLT2 [inhibitors], we need to start patients on them early, keep them on them, and not stop the drug," Herrington said at the late-breaking session.
Because this list isn't complete ... If you have type 2 diabetes, you can choose a similar SGLT2 inhibitor to Jardiance, such as Invokana (canagliflozin). Because both drugs stop a protein that ...
The FDA is expected to decide on treatments for familial chylomicronemia syndrome, type 1 diabetes, short bowel syndrome, and Prader-Willi syndrome.
The retrospective study looked at people with type 2 diabetes who started diabetes medication from 2014 to 2019 in South Korea. People taking SGLT2 inhibitors were matched with people taking other ...
Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine and scientific director at The American Federation for Aging Research (AFAR), predicts it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback